Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Greenhill Gains as Firm Plays Adviser to Actavis

Greenhill & Co. gained the most in more than two years after the firm acted as sole adviser to Actavis Plc in its $25 billion bid for Forest Laboratories Inc.

Greenhill, founded by former Morgan Stanley President Robert F. Greenhill, rose 8.7 percent to $52.98 at 4:15 p.m. in New York. The rally buoyed the stock after a 16 percent slide this year through last week, following a fourth quarter that included a 25 percent drop in advisory revenue.

“There was definitely a great deal of relief to see them on a large deal,” said Brennan Hawken, an analyst at UBS AG, who assigns a neutral rating to the stock. “Often when you have a deal that big, there is more than one adviser. They are getting all the revenue on the buy side.”

Hawken said the stock had become a target of short-sellers, who are probably buying today to cut their losses after betting on a further decline. Jeffrey Taufield, Greenhill’s spokesman, said in an e-mail that the company had no comment.

Actavis, the world’s second-largest generic-drug maker by market value, is seeking to become a developer of brand-name drugs.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.